

ESPS Peer-review Report

Name of Journal: World Journal of Cardiology

ESPS Manuscript NO: 6248

Title: Duration of Dual Antiplatelet Treatment in the Era of Next Generation Drug-eluting Stents

Reviewer code: 00070848

Science editor: Wen, Ling-Ling

Date sent for review: 2013-10-11 14:35

Date reviewed: 2013-10-15 03:54

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This review is a summary of important trials concerning the optimal duration of dual antiplatelet treatment following DES implantation, particularly in patients underwent PCI with next generation DESs. Since the risks and benefits of long-term dual antiplatelet therapy remain unclear such a summary is important. However, the authors: 1. Should add an abstract 2. Should ask for permission for using tables already published in other Journals 3. Should add and comment on the recent optimal dual antiplatelet therapy (OPTIDUAL) see Trials 2013 Feb 21;14:56 4. Should add and comment on the Korean "Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation: A Randomized Controlled Trial" published this month (October 2013) in "Circulation". 5. Should comment on and add as reference the papers (Int J Cardiol. 2012 Apr 19;156(2):125-32 and Thromb Res. 2013 Aug;132(2):312.) emphasizing the hypersensitivity responses following stent implantation in association with thrombosis, bleeding and clopidogrel.

ESPS Peer-review Report

Name of Journal: World Journal of Cardiology

ESPS Manuscript NO: 6248

Title: Duration of Dual Antiplatelet Treatment in the Era of Next Generation Drug-eluting Stents

Reviewer code: 00225245

Science editor: Wen, Ling-Ling

Date sent for review: 2013-10-11 14:35

Date reviewed: 2013-10-17 14:28

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

Topic of the submitted paper is on the front burner of current cardiology. Essential data have been thoroughly collected and I have no major critical comment. Author should correct typo error on page 10 (abbr. TUMI).

ESPS Peer-review Report

Name of Journal: World Journal of Cardiology

ESPS Manuscript NO: 6248

Title: Duration of Dual Antiplatelet Treatment in the Era of Next Generation Drug-eluting Stents

Reviewer code: 00225260

Science editor: Wen, Ling-Ling

Date sent for review: 2013-10-11 14:35

Date reviewed: 2013-10-17 20:04

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D (Fair)		BPG Search:	<input checked="" type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

Rha aims to give an overview on role of the duration of dual antiplatelet treatment in the era of new drug-eluting stents. There are major problems and flaws: 1. The author just copied a couple of summaries of the respective trials in one manuscript 2. the figures were just taken from the original papers. A general scheme/new summary figure would improve the manuscript. 3. What about the novel P2Y12 inhibitors? How does the clinical setting (ACS/NSTEMI/STEMI, stable CAD) influence the antithrombotic strategy 4. what is novel about this paper?